Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IRIX's Cash to Debt is ranked higher than
95% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. IRIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
IRIX' s 10-Year Cash to Debt Range
Min: 0.38  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.81
IRIX's Equity to Asset is ranked higher than
74% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. IRIX: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
IRIX' s 10-Year Equity to Asset Range
Min: 0.4  Med: 0.83 Max: 0.94
Current: 0.81
0.4
0.94
Interest Coverage No Debt
IRIX's Interest Coverage is ranked higher than
93% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. IRIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IRIX' s 10-Year Interest Coverage Range
Min: 6.53  Med: 10000.00 Max: 9999.99
Current: No Debt
6.53
9999.99
F-Score: 6
Z-Score: 6.81
M-Score: 0.22
WACC vs ROIC
17.21%
1881.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.53
IRIX's Operating margin (%) is ranked higher than
58% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. IRIX: 5.53 )
Ranked among companies with meaningful Operating margin (%) only.
IRIX' s 10-Year Operating margin (%) Range
Min: -43.43  Med: 4.29 Max: 15.91
Current: 5.53
-43.43
15.91
Net-margin (%) 22.64
IRIX's Net-margin (%) is ranked higher than
94% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. IRIX: 22.64 )
Ranked among companies with meaningful Net-margin (%) only.
IRIX' s 10-Year Net-margin (%) Range
Min: -40.11  Med: 5.98 Max: 23.45
Current: 22.64
-40.11
23.45
ROE (%) 33.63
IRIX's ROE (%) is ranked higher than
97% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. IRIX: 33.63 )
Ranked among companies with meaningful ROE (%) only.
IRIX' s 10-Year ROE (%) Range
Min: -87.4  Med: 6.49 Max: 33.69
Current: 33.63
-87.4
33.69
ROA (%) 26.93
IRIX's ROA (%) is ranked higher than
98% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.22 vs. IRIX: 26.93 )
Ranked among companies with meaningful ROA (%) only.
IRIX' s 10-Year ROA (%) Range
Min: -51.3  Med: 5.29 Max: 26.59
Current: 26.93
-51.3
26.59
ROC (Joel Greenblatt) (%) 18.97
IRIX's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. IRIX: 18.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IRIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -186.08  Med: 12.66 Max: 28.34
Current: 18.97
-186.08
28.34
Revenue Growth (3Y)(%) 8.40
IRIX's Revenue Growth (3Y)(%) is ranked higher than
69% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. IRIX: 8.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IRIX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.9  Med: 4.90 Max: 24.8
Current: 8.4
-21.9
24.8
EBITDA Growth (3Y)(%) -2.20
IRIX's EBITDA Growth (3Y)(%) is ranked lower than
56% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. IRIX: -2.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IRIX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -44.2  Med: -0.70 Max: 178.1
Current: -2.2
-44.2
178.1
EPS Growth (3Y)(%) 66.50
IRIX's EPS Growth (3Y)(%) is ranked higher than
94% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. IRIX: 66.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IRIX' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.3  Med: 6.85 Max: 255.2
Current: 66.5
-54.3
255.2
» IRIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

IRIX Guru Trades in Q2 2014

Jim Simons 187,600 sh (+10.35%)
» More
Q3 2014

IRIX Guru Trades in Q3 2014

Jim Simons 202,500 sh (+7.94%)
» More
Q4 2014

IRIX Guru Trades in Q4 2014

Jim Simons 210,700 sh (+4.05%)
» More
Q1 2015

IRIX Guru Trades in Q1 2015

Jim Simons 219,800 sh (+4.32%)
» More
» Details

Insider Trades

Latest Guru Trades with IRIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 7.29
IRIX's P/E(ttm) is ranked higher than
96% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. IRIX: 7.29 )
Ranked among companies with meaningful P/E(ttm) only.
IRIX' s 10-Year P/E(ttm) Range
Min: 7.29  Med: 15.14 Max: 220.41
Current: 7.29
7.29
220.41
Forward P/E 18.42
IRIX's Forward P/E is ranked higher than
61% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.26 vs. IRIX: 18.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 7.30
IRIX's PE(NRI) is ranked higher than
95% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 28.30 vs. IRIX: 7.30 )
Ranked among companies with meaningful PE(NRI) only.
IRIX' s 10-Year PE(NRI) Range
Min: 7.28  Med: 28.43 Max: 216
Current: 7.3
7.28
216
P/B 2.03
IRIX's P/B is ranked higher than
68% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. IRIX: 2.03 )
Ranked among companies with meaningful P/B only.
IRIX' s 10-Year P/B Range
Min: 0.41  Med: 1.71 Max: 4.1
Current: 2.03
0.41
4.1
P/S 1.65
IRIX's P/S is ranked higher than
68% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. IRIX: 1.65 )
Ranked among companies with meaningful P/S only.
IRIX' s 10-Year P/S Range
Min: 0.11  Med: 1.28 Max: 2.83
Current: 1.65
0.11
2.83
PFCF 23.24
IRIX's PFCF is ranked higher than
66% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 30.88 vs. IRIX: 23.24 )
Ranked among companies with meaningful PFCF only.
IRIX' s 10-Year PFCF Range
Min: 0.29  Med: 40.20 Max: 355.5
Current: 23.24
0.29
355.5
POCF 18.34
IRIX's POCF is ranked higher than
62% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 21.63 vs. IRIX: 18.34 )
Ranked among companies with meaningful POCF only.
IRIX' s 10-Year POCF Range
Min: 2.53  Med: 28.29 Max: 175.67
Current: 18.34
2.53
175.67
EV-to-EBIT 23.74
IRIX's EV-to-EBIT is ranked lower than
52% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 21.84 vs. IRIX: 23.74 )
Ranked among companies with meaningful EV-to-EBIT only.
IRIX' s 10-Year EV-to-EBIT Range
Min: -56.1  Med: 21.80 Max: 2786.4
Current: 23.74
-56.1
2786.4
Shiller P/E 17.95
IRIX's Shiller P/E is ranked higher than
81% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 30.75 vs. IRIX: 17.95 )
Ranked among companies with meaningful Shiller P/E only.
IRIX' s 10-Year Shiller P/E Range
Min: 17.92  Med: 88.57 Max: 1080
Current: 17.95
17.92
1080
Current Ratio 4.60
IRIX's Current Ratio is ranked higher than
71% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. IRIX: 4.60 )
Ranked among companies with meaningful Current Ratio only.
IRIX' s 10-Year Current Ratio Range
Min: 1.02  Med: 5.47 Max: 13.85
Current: 4.6
1.02
13.85
Quick Ratio 3.24
IRIX's Quick Ratio is ranked higher than
66% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. IRIX: 3.24 )
Ranked among companies with meaningful Quick Ratio only.
IRIX' s 10-Year Quick Ratio Range
Min: 0.62  Med: 4.14 Max: 12.25
Current: 3.24
0.62
12.25
Days Inventory 163.46
IRIX's Days Inventory is ranked lower than
63% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 131.01 vs. IRIX: 163.46 )
Ranked among companies with meaningful Days Inventory only.
IRIX' s 10-Year Days Inventory Range
Min: 124.26  Med: 174.67 Max: 286.28
Current: 163.46
124.26
286.28
Days Sales Outstanding 67.63
IRIX's Days Sales Outstanding is ranked higher than
51% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.21 vs. IRIX: 67.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRIX' s 10-Year Days Sales Outstanding Range
Min: 58.34  Med: 78.89 Max: 158.95
Current: 67.63
58.34
158.95

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.94
IRIX's Price/Net Cash is ranked higher than
53% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 14.23 vs. IRIX: 13.94 )
Ranked among companies with meaningful Price/Net Cash only.
IRIX' s 10-Year Price/Net Cash Range
Min: 2.69  Med: 5.44 Max: 250
Current: 13.94
2.69
250
Price/Net Current Asset Value 2.75
IRIX's Price/Net Current Asset Value is ranked higher than
89% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 6.53 vs. IRIX: 2.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IRIX' s 10-Year Price/Net Current Asset Value Range
Min: 0.74  Med: 2.00 Max: 125.71
Current: 2.75
0.74
125.71
Price/Tangible Book 2.07
IRIX's Price/Tangible Book is ranked higher than
79% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. IRIX: 2.07 )
Ranked among companies with meaningful Price/Tangible Book only.
IRIX' s 10-Year Price/Tangible Book Range
Min: 0.66  Med: 1.91 Max: 26.67
Current: 2.07
0.66
26.67
Price/Projected FCF 1.47
IRIX's Price/Projected FCF is ranked higher than
71% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. IRIX: 1.47 )
Ranked among companies with meaningful Price/Projected FCF only.
IRIX' s 10-Year Price/Projected FCF Range
Min: 0.69  Med: 1.85 Max: 17.3
Current: 1.47
0.69
17.3
Price/Median PS Value 1.29
IRIX's Price/Median PS Value is ranked lower than
60% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. IRIX: 1.29 )
Ranked among companies with meaningful Price/Median PS Value only.
IRIX' s 10-Year Price/Median PS Value Range
Min: 0.12  Med: 1.02 Max: 6.22
Current: 1.29
0.12
6.22
Price/Graham Number 0.80
IRIX's Price/Graham Number is ranked higher than
91% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 2.46 vs. IRIX: 0.80 )
Ranked among companies with meaningful Price/Graham Number only.
IRIX' s 10-Year Price/Graham Number Range
Min: 0.86  Med: 1.68 Max: 4.08
Current: 0.8
0.86
4.08
Earnings Yield (Greenblatt) (%) 4.22
IRIX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. IRIX: 4.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IRIX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 3.30 Max: 7.8
Current: 4.22
0.1
7.8
Forward Rate of Return (Yacktman) (%) 7.21
IRIX's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 99 Companies
in the Global Medical Devices industry.

( Industry Median: 4.14 vs. IRIX: 7.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IRIX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -34.3  Med: 0.65 Max: 22.5
Current: 7.21
-34.3
22.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:IX4.Germany,
Iridex Corp was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, the Company changed its name to IRIDEX Corporation and reincorporated in Delaware. It is a provider of therapeutic based laser systems, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. Its ophthalmology products consist of laser console, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases, including the three causes of irreversible blindness: diabetic retinopathy, glaucoma and age-related macular degeneration. In addition, its ophthalmology products are often used in vitrectomy procedures which are generally performed in the operating room and require a consumable single use intraocular laser probe to deliver the light to the back of the eye. Its laser systems consist of IQ products which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems; and its OcuLight products including OcuLight TX, OcuLight Symphony, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. The Company utilizes a systems approach to product design. Each system includes a console, which generates the laser energy, and a number of interchangeable peripheral delivery devices for use in specific clinical applications. Customers include research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. The Company sells and markets its products in the United States predominantly through its direct sales force and internationally through approximately 70 independent distributors into over 100 countries. The Company has been issued 26 United States patents and 17 foreign patents. It is subject to extensive regulation by numerous governmental authorities, including federal, state, and foreign governmental agencies.
» More Articles for IRIX

Headlines

Articles On GuruFocus.com
IRIDEX Corp. Reports Operating Results (10-Q) Nov 04 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 05 2010 
IRIDEX Corp. Reports Operating Results (10-Q) May 06 2010 
IRIDEX Corp. Reports Operating Results (10-Q) Nov 12 2009 
IRIDEX Corp. Reports Operating Results (10-Q) Aug 13 2009 
IRIDEX Reports Second Quarter 2009 Financial Results Aug 13 2009 
IRIDEX Corp. Reports Operating Results (10-Q) May 15 2009 
IRIDEX Corp. (IRIX) CFO James H Mackaness buys 2,000 Shares Mar 13 2009 

More From Other Websites
IRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 16 2015
IRIDEX Announces Preliminary Revenues for 2015 Second Quarter Jul 16 2015
IRIDEX Announces Preliminary Revenues for 2015 Second Quarter Jul 16 2015
IRIDEX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 19 2015
Edited Transcript of IRIX earnings conference call or presentation 7-May-15 9:00pm GMT Jun 18 2015
IRIDEX to Present at LD Micro Invitational May 28 2015
IRIDEX to Present at LD Micro Invitational May 28 2015
IRIDEX CORP Financials May 20 2015
10-Q for IRIDEX Corp. May 14 2015
IRIDEX to Present at UBS Global Healthcare Conference May 13 2015
IRIDEX to Present at UBS Global Healthcare Conference May 13 2015
IRIDEX CORP Files SEC form 10-Q, Quarterly Report May 12 2015
Iridex posts 1Q profit May 07 2015
Iridex posts 1Q profit May 07 2015
IRIDEX Corp Earnings Call scheduled for 5:00 pm ET today May 07 2015
IRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2015
IRIDEX Reports 2015 First Quarter Results May 07 2015
Q1 2015 IRIDEX Corp Earnings Release - After Market Close May 07 2015
IRIDEX Announces First Quarter 2015 Conference Call and Release Date Apr 30 2015
IRIDEX Announces First Quarter 2015 Conference Call and Release Date Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK